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Renal growth hormone—insulin-like growth factor-I system in acute
renal failure. The renal growth hormone—insulin-like growth factor-I
system in acute ischemic renal failure. Recovery from acute tubular
necrosis (ATN) is accelerated by IGF-I therapy. Furthermore, the local
renal growth hormone-IGF-I system may participate in the natural repair.
We examined the IGF-I system in rat kidneys subjected to 60 minute
ischemia compared to sham operated controls. Two days after injury,
growth hormone receptor mRNA and IGF-I mRNA levels fell —9 to 33%
of control values. This was associated with a reduction in kidney immu-
noreactive IGF-I levels. In contrast, IGF-I receptor mRNA abundance
was unchanged. However, plasma membrane IGF-I receptor binding on
day 2 and day 7 was near double the control values (P < 0.01). Scatchard
analysis revealed a near twofold increase in receptor number. Since
receptor mRNA levels were unchanged, this implies receptor protein
up-regulation. In contrast to unchanged IGF-I receptor mRNA levels, the
abundance of mRNA levels of insulin-like growth factor binding proteins
(IGFBP) -2, -3, -4 and -5 fell —14 to 62% of control levels day 2 after
injury (P < 0.05), suggesting reduced IGFBP production. Thus, the renal
response to ischemic ATN, namely, low IGFBP mRNA levels and high
IGF-I receptor number, may function to increase IGF-I bioavailability and
thereby enhance the reparative actions of local and circulating IGF-I in
ischemic ATN.
Acute tubular necrosis (ATN) is a relatively common, poten-
tially life threatening clinical occurrence [11. Since growth factors
play an important role in the regeneration of damaged renal
tubular epithelium several studies have examined the ability of
selected growth factors to modulate the course of experimental
ATN in the rat. Earlier studies indicated that epidermal growth
factor (EGF) [2, 3] is effective, and recently we and others have
demonstrated that IGF-I treatment of ischemic ATN with IGF-I
or its analog des(1—3)IGF-I attenuates the severity and duration
of acute renal failure [4—61. The manner in which IGF-I mediates
its salutary effect on the course of acute renal failure is complex
and not fully understood. IGF-I has been shown to enhance renal
blood flow and glomerular filtration rate [7], stimulate tubular cell
proliferation [8, 91 and cellular differentiation [10]. Also, IGF-I is
potently anabolic and this may favor tubular cell recovery [11].
IGF-I is synthesized in most tissues, but most of the circulating
IGF-I is derived from the liver [121. The kidney is an important
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source of IGF-I, the production of which is influenced by growth
hormone (Gil) [13, 14]. Recent reports reviewed by Jennische,
Isgaard and Isaksson [15] suggest that locally produced IGF-I may
play a role in tissue repair. In several tissues, including kidney,
skeletal muscle, CNS neurons, aortic smooth muscle and endo-
thelium there is an increase in local IGF-I expression after injury.
Since locally produced IGF-I may play a role in the natural
regenerative process and as administration of recombinant IGF-I
enhances recovery from ischemic ARF, we set out to characterize
the changes in the renal GH-IGF-I system following acute isch-
ernie renal failure. This system includes IGF-I, six insulin-like
growth factor binding proteins (IGFBP) and the receptors for
IGF-I and GH [12, 14]. The binding proteins, also present in the
circulation, have a high affinity for IGF-I and serve as a carrier or
reservoir for the hormone and modulate its bioactivity [16, 17].
We reasoned that information from our study would provide new
insight into the role of IGF-I in the restoration of renal structure
and function, and assist in the design of rational therapeutic
approaches for the use of IGF-I in the treatment of acute renal
failure. To this end we have utilized a rat model of ischemic acute
renal failure.
Methods
Animals
Male Sprague-Dawley rats weighing 250 to 300 g were anesthe-
tized with sodium methohexital 50 mg/kg body weight i.p. The
kidneys were then exposed via a flank incision. In half the rats the
renal pedicle was clamped; the other rats served as a sham-
operated control group. The wounds were then covered with
gauze. After 60 minutes the clamps were removed and the wounds
of all the animals were suture closed. Rats were returned to their
cage and allowed ad libitum access to food and water. Dietary
intake in these rats was not controlled since we wished, as a first
step, to characterize the renal response in a model that simulates
the clinical situation. Serum creatinine was measured in tail vein
blood. Experimental rats that did not achieve a serum creatinine
above 2 mg/dl after two days were excluded from the study. Rats
were sacrificed under anesthesia two or seven days after surgery.
For rnRNA analysis kidneys were rapidly excised, blotted and
frozen in liquid nitrogen. For measurement of kidney IGF-I
content and receptor binding analysis, kidneys were saline per-
fused via the aorta until free of blood. In another set of experi-
ments weight matched sham operated controls and ATN rats were
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pair fed to control for any response due to the reduced dietary
intake that accompanies uremia. These rats were studied two days
after injury.
Preparation of "crude" kidney plasma membranes
Tissues from one and a half whole kidneys were minced, added
to cold 8% wt/wt sucrose buffer and then disrupted with 15 gentle
strokes in a dounce homogenizer. The homogenate was centri-
fuged at 1000 g for 10 minutes and the supernate collected. The
pellet was disrupted with 10 strokes in a homogenizer containing
10 ml sucrose buffer and then centrifuged at 1000 g for 10 minutes.
The supernates were pooled and spun at 9,500 g for 10 minutes.
The supernate and soft light upper pellet were removed from the
central dark pellet and then mixed prior to centrifugation at
47,000 g for 20 minutes. The soft light fluffy upper pellet was
removed and resuspended in 1 ml calcium free Krebs-Ringers
Hepes (KRH) buffer and washed twice and stored at —80°C until
use. All steps were carried out at 4°C.
IGF-I binding assays
Recombinant hIGF-1, a gift from Genentech Inc. (South San
Francisco, CA, USA), was radiolabeled with 1251-Na (< one
iodine atom/molecule) by a chloramine T method [181. The
binding of 1251-IGF-I to crude kidney plasma membranes was
determined as follows. Calcium-free KRH buffer containing 0.5%
BSA with or without various concentrations of unlabeled IGF-I
and other cold peptide hormones were added to the same buffer
containing 10_Il M '251-IGF-I and 2 mi bacitracin and 5 m
N-ethylmaleimide. The membrane suspension containing 60 tg of
protein was then added and incubated at 4°C overnight. Mem-
brane-bound and free 1251-IGF-I were separated by centrifugation
at 12,000 g for 15 minutes and the supernatants aspirated. The
membrane pellets were washed once with the KRH buffer and the
tips of the centrifuge tubes excised. '251-radioactivity was deter-
mined in a gamma counter. Nonspecific binding was defined as
the counts of '251-IGF-I remaining associated with membranes in
the presence of 10_6 M of unlabeled IGF-1, and is subtracted from
total binding to yield specific binding. With 1251-IGF-I non-
specific binding averaged 1.9 0.18%. The data from competition
curves were subjected to Scatchard analysis to determine binding
affinity and receptor number [19]. 1251-IGF-I degradation in the
binding assays was assessed as the appearance of radioactivity
soluble in 10% trichloroacetic acid (TCA) and averaged 4.3% of
total counts.
Cross linking of '251-IGF-I receptor
'251-IGF4 was cross linked to kidney membranes essentially as
described by Pillion, Haskell and Meezan [201. Aliquots of crude
membrane preparations equivalent to 200 jg of protein were
incubated overnight at 4°C with 10_b M radiolabeled I-IGF-I in
the absence or presence of i0- M unlabeled IGF-I or insulin. The
membranes were washed twice in BSA-free Krebs-Ringers Hepes
buffer (KRH), pH 7.5. Cross linking of the alpha1 subunit of IGF-1
receptor was allowed in KRH in the presence of 0.25 mM
disuccinimidyl suberate at 4°C for 15 minutes. The cross linking
was terminated by the addition of 10 ifiM Tris-HCI with I ifiM
EDTA, pH 7.5. The pellets were washed twice and were resus-
pended in 20 p.! of sample buffer in the presence of 1% 2-mer-
captoethanol as a reducing agent, heated at 95°C for 90 seconds,
and subjected to 5 to 15% gradient SDS-polyacrylamide gel
electrophoresis. The radioactivity in the gel was analyzed by
autoradiography. Molecular weights were determined by compar-
ison with prestained markers from BioRad (Richmond, CA,
USA).
Western ligand blot
Plasma membranes were prepared from saline perfused blood-
less whole kidneys as described earlier. Membrane protein, 60 p.g,
pooled from five rats was electrophoresed in 12% polyacrylamide
gel. Separated proteins were electroblotted onto nitrocellulose
filters with a BioRad Semi-Dry Transfer Cell and then incubated
with a mixture of 1251-IGF-I and '251-IGF-II overnight at 4°C and
visualized by autoradiography [21]. Cytosolic protein (10,000 g
supernate) was also examined in the same manner, but no signal
was detected with 100 p.g cytosolic protein.
Estimation of serum and kidney concentrations of IGF-I
using RIA
IGF-1 was extracted from serum and bloodless saline perfused
kidneys before measurement by radioimmunoassay. Before har-
vesting, kidneys were briefly perfused with saline in vivo to render
them blood free. The extraction method used was based on that
described by D'Ercole, Stiles and Underwood [22] and acid-
separates IGF-I from its binding proteins. This procedure gives
values comparable to that obtained following high pressure liquid
chromatography separation [23]. A quarter of a kidney from each
rat was homogenized in 1 M acetic acid and the acid extract
assayed for IGF-I and corrected for recoveries. Serum IGF-I was
extracted with acid ethanol. IGF-I was measured with a radioim-
munoassay kit (Nichols Institute, San Juan Capistrano, CA,
USA). Recovery of recombinant IGF-I added to control and ATN
kidney homogenates averaged 85 1 and 95 1.7%, respectively,
and to serum 88 3.2 and 94 3.4%, respectively.
Preparation of RNA
Total kidney RNA was isolated using the single step method of
Chomczynski and Sacchi [24]. A quarter of a kidney from each rat
was homogenized, and RNA was extracted using acid guani-
dinium thiocyanate-phenol-chloroform and then spectrophoto-
metrically quantified by determining absorbance at 260 nm. The
integrity of RNA was checked by inspecting the fluorescence of
ethidium bromide stained I 8S and 28S rRNA bands separated by
agarose gel electrophoresis.
Solution hybridization/RNase protection assay
Protection assays were performed as previously described [25].
Total RNA (20 p.g) was hybridized with 100,000 cpm of a-32P
CTP labeled antisense IGF-I or IGF-I receptor riboprobes and
5,000 cpm of antisense GAPDH riboprobe for 14 hours at 55°C in
80% formamide/400 mivi NaCl buffer. After hybridization, the
mixture was digested with ribonuclease A (10 p.g/ml) and ribonu-
clease Ti (100 U/mI) at 37°C for 30 minutes and then proteinase
K (200 p.g/ml) at 37°C for 30 minutes, Protected hybrids were
size-separated on a 5% polyacrylamide/8 M urea denaturing gel
and analyzed by autoradiography.
Northern blot analysis
Total RNA was size-separated by agarose gel electrophoresis.
Briefly, RNA was denatured with 0.55 M formaldehyde. Twelve
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micrograms of RNA was loaded in each lane and electrophoresed
on a denaturing agarose gel containing 0.55 M formaldehyde.
RNA was transferred by capillary action onto nitrocellulose filters
and then fixed to the filters by UV cross linking (UV 1800
Stratalinker; Stratgene, La Jolla, CA, USA). The filters were then
prehybridized in the hybridization solution (50% formamide, 1.5
X SSPE, 2.5 x Denharts solution, 50 jg salmon sperm DNA,
0.2% SDS) at 42°C for two hours. The mRNA levels of IGFBP-1,
-2, -3, -4, and -5 were detected by hybridizing radiolabeled cDNA
probes to the mRNA. Probes, —2.5 million cpmlml, were hybrid-
ized to the respective mRNAs on Northern blots in a fresh
hybridization solution at 42°C overnight. The filters were then
washed and exposed to Kodak XAR films (Kodak, Rochester,
NY, USA) at — 70°C for one to five days. Where noted the filters
were then reprobed with a hGAPDH eDNA probe. The mRNA
abundance of each IGFBP was analyzed by densitometry (Ultra-
scan XL, Pharmacia LKB Biotechnology, Inc., Alameda, CA,
USA) and corrected for either the levels of the GAPDH mRNA
readings or the I 8S mRNA readings obtained from photographic
negatives of the nitrocellulose filters. In preliminary experiments
we found that GAPDH mRNA levels in kidneys two and seven
days post-ischemia did not differ from that measured in sham-
operated control kidneys. A linear relationship was present be-
tween the optical density (OD) of the photographic negative of
the nitrocellulose 18S mRNA signal and the total RNA content
up to 30 jg (r = 0.99).
Polymerase chain reaction (PCR) assay
Relative levels of renal GH receptor mRNA were assayed by
using a gene Amp RNA-PCR kit (Perkin Elmer Cetus, Norwalk,
CT, USA) [26]. Total RNA was reverse transcribed by using
random hexamers. The oligonucleotide primers for the GH
receptor were designed to amplify a 321 base pair DNA fragment.
The fragment included 97 bases in exon 5 and 145 bases in exon
7. Both exons are in the extracellular domain of the rat GH cDNA
sequence [27]. GH receptor mRNA was amplified by 28 PCR
cycles and as an internal amplification control, 18S rRNA was
amplified in the same assay tube for the last 10 cycles by adding
specific 18S rRNA primers. The 18S rRNA primers amplified 140
bases spanning nucleotide positions 107 to 246 in the human
cDNA sequence [28]. PCR products were separated on a 5%
polyacrylamide!8 M urea gel and analyzed by quantitative autora-
diography.
Preparation of radiolabeled probes
For the solution hybridization/RNase protection assay, labeled
antisense IGF-I, IGF-I receptor and GAPDH riboprobes were
synthesized using 32P-labeled CTP as previously described [25].
The IGF-I riboprobe, a 376 bp Sau3A-EcoRI fragment was
designed to detect both the Ea and Eb IGF-I mRNAs [29]. The
IGF-I receptor riboprobe contained 280 bases complementary to
the IGF-I receptor mRNA. For Northern blot analysis the eDNA
probes were labeled with 50 tCi [32P] dCTP (3000 Ci/mmol,
Amersham, Arlington Heights, IL, USA) by a random primer
method (DNA labeling kit 70200; United States Biochemical
Corporation, Cleveland, OH, USA). Radiolabeled cDNA probes
were purified by centrifugation through a G-50 Sephadex column.
The cDNA probes for the five IGFBPs studied were derived
from rat cDNAs cloned into recombinant plasmid vectors (pBlue-
scriptSK+) which were gifts of Dr. S. Shimasaki (Whittier Insti-
tute, La Jolla, CA, USA). The probes were obtained by synthe-
sizing the corresponding cDNA by PCR using the cloned cDNA
as a template. The molecular characteristics of the rat cDNAs
have recently been reviewed by Shimasaki and Ling [30]. The
IGFBP-1 probe comprised 407 bp corresponding to the coding
region spanning nucleotide position 486 to 892 in the rat IGFBP-1
cDNA sequence. The IGFBP-2 probe consisted of 342 bp span-
fling nucleotide position 670 to 1011. The IGFBP-3 probe com-
prised 636 bp spanning nucleotide positions 196 to 831. The
IGFBP-4 probe comprised 384 bp spanning nucleotide position
457 to 840. The IGFBP-5 probe comprised 259 bp spanning
nucleotide position 856 to 1114.
Data analysis
Densitometry readings of the mRNAs of interest were cor-
rected for the corresponding GAPDH mRNA or 18S RNA
reading. For IGF-I we quantified the Ea IGF-I mRNA transcripts
only since it accounted for >95% of the IGF-1 mRNA signal.
Results are expressed as the mean SEM. The mean of the
controls was assigned a value of unity and all results were
expressed in relation to this value. Differences between the
control and experimental groups were evaluated using Student's
two-tailed unpaired t-test. P values of <0.05 were considered
significant.
Results
Ad libitum fed rats
Following bilateral renal pedicle clamping the serum creatinine
rose, reaching a maximum after 24 hours. After the second day the
serum creatinine, which averaged 4.2 0.32 mg/dl, declined (Fig.
1). By the seventh day serum creatinine levels had fallen consid-
erably but were still more than double the baseline values (1.0
0.4 vs. 0.4 0.04 mg/dl). Changes in body weight differed
significantly (P < 0.01) between the two groups after the experi-
mental intervention (Table 1). Two days post-injury ATN rats lost
27 g while the body weight of the controls had not changed. On
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Fig. 1. Serum creatinine following a sham operation (•, controls) or 60
minutes of renal ischemia with acute tubular necrosis (EI A TN). Results are
the mean SEM from 3 to 6 ad libitum fed rats per time point. *p < 0.05,
< 0.01.
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Table 1. Body weight changes () and serum creatinine levels in rats with ischemic acute tubular necrosis (ATN), and in ad libitum or pair-fed
sham operated controls
Day2 Day7
Control ATh Control ATh
Ad-libitum diet
Bodyweight,g 0± 2.1(N= 15) —27 1.4(N= 11) 25 10(N= 8) —17 10,5(N= 8)
Serum creatinine mg/dl 0.36 0.04 (N = 20) 4.19 0.32 (N = 20)
Pair-fed diet
Body weight, g 25 1.6 (N = 5) 24 3.2 (N 5)
Serum creatinine mg/dl 0.38 0.02 (N = 5) 3.68 0.02 (N = 5)
Data are SEM.
ap < 0.01 vs. control
20
were especially concerned with the possibility that the IGFBPs
might interfere with IGF-I receptor binding. As shown in Figure
2, displacement of 1251-IGF-I by unlabeled IGF-I or des(1-
3)IGF-I was near identical. Since des(1-3)IGF-I has a low affinity
for IGFBPs [11] this suggests that 1251-IGF-I binding to kidney
membranes represents receptor binding. In the same figure the
effect of insulin is shown. Insulin was approximately three orders
of magnitude less effective than IGF-I in displacing 1251-IGF-I
from its receptor. In separate experiments (not shown), IGF-II
was about one order of magnitude less effective than IGF-I in
displacing labeled IGF-I from its receptor. These results indicate
0 1 2 3 4 5 6 that at physiologic IGF-I concentrations '251-IGF-I binding to
kidney membranes is essentially receptor specific.
When measured on day 2 after surgery, specific IGF-I binding
to kidney membranes from postischemic rats was twofold greater
than the controls (13.9 1.6 vs. 7.7 0.4%/60 g protein, P <
0.01). On day 7 there was a similar increase in binding to the
post-ischemic membranes (14.6 1.3 vs. 8.1 0.4%, P < 0.01).
It is notable that the extent of specific IGF-I receptor binding
correlates significantly with the serum creatinine levels measured
on day 2 (Fig. 3). This suggests that the degree of injury may have
influenced the receptor response. The differences between the
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Fig. 2. Competitive inhibition of '251-IGF-I binding to kidney plasma
membrane from normal rats. Various concentrations of IGF-I, (El) des(1-
3IGF-I (•) and insulin (0) were added to membranes incubated with
1 51-IGF-I (10—11 M). Data are corrected for non-specific binding.
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Fig. 4. Competitive inhibition of '251-IGF-I binding to kidney plasma
membranes from control (El) and ischemic A TN (•) rats. Results are the
mean of two separate experiments two days after surgery. Similar results
were obtained on day 7. In the insert the data is expressed as a percent of
maximal binding.
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Fig. 3. Relationship between the specific binding of '251-IGF-I (10_21 M) to
kidney plasma membranes and the sensm creatinine level from control and
ATN rats two days after suigely. r = 0.91; P < 0.01.
day 7, the ATN rats were still 17 g below their starting weights,
while control rats had gained 25 g.
For the IGF-I receptor binding study, we first tested the
specificity of ligand binding to normal rat kidney membranes. We
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control and ATN groups is readily apparent from the displace-
ment curves shown in Figure 4. When the data were expressed as
a percent of maximum 1251-IGF-I bound, the displacement curves
were superimposable (Fig. 4 insert). These curves were used to
determine the concentration of recombinant IGF-I at which
1251-.IGF4 binding was 50% of maximum, a measure of relative
receptor affinity. For control and experimental membranes from
day 2 and 7 this averaged 2 and 1.4 nM, respectively. These
findings suggest that receptor affinity was similar in these two
groups. Scatchard analysis of the high affinity binding components
revealed that receptor affinity (0.4 nM) was the same in both
groups, while receptor number was increased more than twofold
following ATN compared to the controls (125 vs. 54 pM/60 g
membrane protein).
The specificity of IGF-I receptor binding in control and post-
ischemic membranes was further demonstrated by IGF-I receptor
covalent cross linking experiments. The autoradiogram depicted
in Figure 5 shows 1251-IGF-I bound to a protein of Mr — 130 kDa
which is compatible with the alpha1 subunit of the IGF-I receptor.
Binding was blocked by iO M IGF-I, but not by insulin. While
both sets of membranes were exposed to the same '251-IGF-I
concentration, labeling of the ATN membranes was more intense,
in keeping with a greater number of receptors in the ATN
membranes.
In contrast to the change in receptor protein number there was
no significant difference in relative IGF-I receptor mRNA abun-
dance in post-ischemic kidneys compared to controls two or seven
days after surgery (Fig. 6). This indicates that the increase in
IGF-I receptor number in the injured kidneys is a consequence of
post-translational up-regulation.
The results of the analysis of kidney IGF-I mRNA levels are
shown in Figure 7. In post-ischemic kidneys steady-state IGF-I
mRNA abundance was significantly reduced on day 2 and aver-
aged 21% of the control value. By day 7 relative mRNA abun-
Fig. 5. Autoradiographof 1251-IGF-I (10'° M)
cross-linked to the IGF-I receptorN on kidney mem-
branes from control and A TN rats. Competition
with iO— M unlabeled IGF-I or insulin is shown.
dance had returned to control values. Since kidney production of
IGF-I is in part regulated by Gil [13], we studied GH receptor
gene expression in the ATN kidney two and seven days after the
ischemic injury. As shown in Figure 8, relative GH receptor
mRNA abundance was significantly diminished in the injured
kidneys. On days 2 and 7 the ATN values were on average 9 and
35% of their respective control values.
Next we measured tissue and serum levels of the IGF-I protein
by radioimmunoassay. Serum IGF-I concentrations measured on
days 2 and 7 were similar in the two groups of rats: 1001 100
versus 941 46 and 893 70 versus 864 85 ng/ml, ATN versus
control, respectively. These values are comparable to that re-
ported in normal rats by others [11, 311. Kidney immunoreactive
IGF-I levels were measured on day 2 and were reduced signifi-
cantly in the ATN kidneys compared to controls (5.15 0.56 vs.
7.47 0.44 ng/mg protein, P < 0.01). This is consistent with the
reduced kidney IGF-I mRNA levels observed in this group.
Since IGFBPs modulate IGF-I action, we measured the relative
mRNA abundance of IGFBP-1, -2, -3, -4 and -5 from postischemic
and control rats. Results are depicted in Figure 9. As compared to
controls, the mRNA levels of IGFBP-1 was unchanged. In
contrast the abundance of IGFBP-2, -3, -4 and -5 fell significantly
in the injured kidneys on day 2. The average value of these IGFBP
mRNAs in the ATN group ranged between 4 and 62% of their
respective control values. This was followed by recovery which for
IGFBP-3 and IGFBP-5 was still incomplete on day 7. Western
ligand blot analysis of kidney plasma membranes demonstrated
two IGFBPs of molecular weight approximately 24 and 30 kDa
each (Fig. 10). The signals for both proteins were reduced in the
membranes prepared from rats two days after injury. The OD of
the 24 kDa protein averaged 0.32 and 0.14 arbitrary units in the
control and ATN groups, respectively. The corresponding values
for the 30 kDa protein averaged 0.48 and 0.17 arbitrary units,
Mr (kdal)
2.0
U)
a)>
< 1.5z
E
1.0
IL0
0.5
0.0
Day 2
Fig. 6. Relative IGF-I receptor mRWA levels in kidneys from control orATW
rats studied two or seven days after suigely. IGF-I and GAPDH mRNA
levels were determined simultaneously in solution hybridization-RNase
protection assays. Autoradiograms were quantified by densitometry and
the IGF-l receptor signal was corrected from the GAPDH signal. The
average of the control values were then assigned an arbitrary unit of one
and all readings were expressed relative to this unit. Results are the mean
SEM of 4 to 5 rats per time point. A representative autoradiogram from
day 2 is shown. Note similar GAPDH mRNA levels in control () and
ATN (LI) kidneys.
respectively. This represents a 56 and 65% reduction of the 24 and
30 kDa proteins in ATN.
Pair fed rats
The extent of the renal failure in these experiments judged by
the serum creatinine levels two days after ischemic injury was
comparable to that seen in the ad libitum fed animals (Table 1).
Body weight changes in ATN and pair fed controls were similar.
As noted in the ad libitum experiments kidney IGF-I receptor
mRNA levels, depicted in Figure 11, did not change while plasma
receptor binding increased significantly in the ATN group (20.8
0.77 vs. 8.7 0.67%160 jsg protein; P < 0.01). Steady-state IGF-I
mRNA levels were reduced significantly in the ATN group and
averaged 37% of the pair fed control value (Fig. 11). GM receptor
mRNA abundance was reduced to 11% of the control value (Fig.
11). As shown in Figure 12 there were marked changes in the
IGFBP mRNA profile. The abundance of IGFBP-2, -3, -4 and -5
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Fig. 7. Relative IGF-I mRNA levels in kidneys from control () and ATN
(LI) rats two and seven days after surgery. IGF-I and GAPDH mRNA levels
were measured simultaneously in solution hybridization RNase protection
assays. Results were analyzed and expressed as described in Fig. 6 and are
from 4 to 5 rats per time point. A representative autoradiogram from day
2 is included. < 0.01.
fell significantly after the ischemic episode to values ranging
between 13 and 67% of controls. There was no significant change
in IGFBP-1 mRNA levels.
Discussion
In this study we have demonstrated that acute ischemic kidney
injury is followed by profound alterations in the renal GH—IGF-I
system. These changes were not related to food consumption for
similar patterns were seen whether dietary intake was ad libitum
or controlled. We found that two days after the injury, kidney
IGF-I mRNA levels had declined to approximately 20% of the
value seen in sham-operated control animals allowed free access
to food and water. Kidney immunoreactive IGF-I concentration
was also reduced at this time. After seven days the mRNA levels
had returned to values similar to those measured in the controls.
Presumably the low IGF-I mRNA levels together with the re-
duced IGF-I protein levels indicate that local IGF-I production is
reduced at this time when IGF-I would be of particular value in
the reparative process. In contrast to the fall in kidney IGF-l
concentration the number of IGF-I specific receptors in the
Day2 Day7
I— Control I ATN
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Fig. 8. Relative GH receptor mRNA levels in control (B) andA TN (LI) rats.
GH receptor mRNA and 18S RNA levels were determined simultaneously
by quantitative PCR. The relative GH receptor mRNA levels were
calculated as described in Fig. 6 with the 18S RNA signal substituting for
GAPDH. N = 4 to 6 rats per time point. A representative autoradiograph
from day 2 is shown. *p < 0.05, **p < 0.01.
kidney increased after the ischemic insult. However IGF-I recep-
tor mRNA levels did not differ from control values. Thus the
increase in receptor number appears to reflect a post-translational
response. Also striking was the finding that IGFBP-2, -3, -4, and
-5 mRNA levels were markedly reduced. Indeed two days after
injury the average of these IGFBP mRNA levels ranged between
4 and 62% of their control values. This was accompanied by a
decrease in plasma membrane associated IGFBPs. While this is
consistent with decreased IGFBP production, post-translational
events such as increased proteolytic destruction may also play a
role. By the seventh day, IGFBP-2 and -4 mRNA levels had
returned to control values. As discussed later, the reduction in
IGFBP gene and protein expression could conceivably result in an
increase in the bioavailability of the free circulating IGF-I that
enters the kidney.
Our finding of a decrease in immunoreactive IGF-I levels in the
damaged kidneys is consistent with Ding et a! [6]. On the other
hand, Matejka and Jennische [32], using a non-quantitative mor-
phologic approach, observed that in rats following ischemic injury
the renal distribution of IGF-I became more widespread. IGF-I
immunoreactivity was not limited to the collecting ducts and loop
of Henlé as is seen in normal rat kidneys [12, 33, 341, but was
present in regenerating proximal tubular cells. In addition cells
other than tubular cells, presumably macrophages, expressed
IGF-I. Also IGF-I mRNA, normally limited to the distal nephron,
was more widely expressed appearing in the same sites as the
IGF-I prOtein. These morphologic findings likely reflect a local
response to injury and thus are not incompatible with our
observation that whole kidney IGF-I mRNA and IGF-I protein
levels are reduced.
Using a non-quantitative autoradiographic approach Matejka
and Jennische [321 also noted an increase in IGF-l receptor
binding in the regenerative zone. Taken together with their
observation of a wider expression of IGF-I mRNA, it is likely that
the local increase in immunoreactive IGF-1 reflects IGF-I synthe-
sized locally and IGF-I bound to receptors. Our finding of an
increase in receptor number supports the latter hypothesis. Se-
questration of IGF-I by local IGFBPs provides another potential
mechanism for increased local immunoreactivity. However, the
marked decrease in kidney IGFBP mRNA levels together with the
decrease in kidney IGFBP proteins that we noted argues against
but does not exclude this mechanism.
While interruption of renal blood flow with its attendant
ischemic injury is the initiating event for the observed changes in
the renal IGF-I system, proximate signals mediating these changes
were not examined. Nevertheless, it is worth considering potential
mechanisms involved in these changes. In respect to IGF-I
receptor binding, it appears that the increase in receptor density
represents a post-transcriptional event since there is no corre-
sponding change in mRNA level. Among the possibilities are an
increase in mRNA translation, increased receptor stability or even
a redistribution of cellular receptors from an intracellular location
to the cell surface [35]. Initially the increase in receptor density
could be a response to a decrease in kidney IGF-I production seen
early after injury. The increase in receptor number cannot be
accounted for by reduced food intake [36] since a similar response
was seen when controls were paired with the ATN rats. Interest-
ingly, there was a strong correlation between peak serum creati-
nine levels measured on day 2 and IGF-1 receptor binding
measured two and seven days after the ischemic insult; this
suggests a direct link between the extent of the renal injury and
the receptor response. Up-regulation of receptor number will
likely favor the renal action of circulating and local IGF-I.
Why kidney IGF-I mRNA levels fall after ischemic injury is an
intriguing question since the brunt of the ischemic injury involves
the proximal tubule, a nephron segment where IGF-I is not
normally produced. It is likely that the reduced IGF-I mRNA
levels reflect dysfunction of the cells in the medullary ascending
limb of Henlé and collecting ducts that normally produce IGF-I
[13, 34, 37]. Indeed, while the major site of ischemic injury is the
proximal tubule, less obvious morphologic changes are present in
these more distal nephron segments [38]. This injury probably
accounts for the reduction in IGF-I mRNA levels which may
reflect reduced mRNA production or stability.
Interestingly kidney preproEGF mRNA levels, also expressed
in the ascending loop of Henlé and distal tubule, decline following
ischemic injury [39]. Since EGF stimulates collecting duct IGF-I
gene expression [40], reduced kidney EGF production could
account, in part, for the reduced IGF-I mRNA levels. Growth
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hormone is another potent regulator of kidney IGF-I production
[13]. We found that kidney GH receptor mRNA levels are
reduced in ischemic ATN, and thus propose that reduced GH
signaling may also be a factor accounting for the low kidney IGF-I
mRNA levels. This likely explains the failure of GH therapy to
influence the course of acute ischemic renal failure in rats [51.
Note that the GH receptor mRNA levels were measured with a
primer set that amplified a portion of the rat cDNA which
encodes most of the extracellular domain of the receptor which is
identical to the corresponding part of the serum GH-binding
protein [27]. In the rat there is an alternative splicing event during
the processing of the complete GH receptor mRNA. The full
length transcript forms the complete receptor while the truncated
mRNA encodes the GH-binding protein. This protein has the
same extracellular domain as the GH receptor but lacks a
hydrophobic transmembrane and an intracellular domain. As the
full length GH receptor transcript is predominant in the rat
kidney [41], we conclude that the 35 to 91% reduction in mRNA
levels, detected in our assay, reflects a true lowering of the full
length transcript.
The IGFBPs are important, but poorly understood, compo-
nents of the renal IGF-I system [14]. Six IGFBPs have been
identified and all are expressed in the kidney [30]. Of these
binding proteins, the site of renal production has only been
identified for IGFBP-1 which is localized to the medullary thick
ascending loop of Henlé and collecting ducts [34, 371. Again as
discussed above in the context of IGF-I gene expression, it is not
entirely clear why IGFBP-I mRNA levels fall when the ischemic
injusy is predominantly proximal tubular. The function of each of
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Fig. 9. Relative mRNA levels of IGFBP-I, -2, -3,
-4, and -5 in kidneys from control () or ATN
(LI) rats. mRNA levels were detected by North-
ern blot analysis and corrected for the GAPDH
mRNA levels. Results were analyzed and ex-
pressed as described in Fig. 6 and are from 3 to
5 rats per time point. Representative Northern
blots are shown. *P < < 0.01.
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Mr(kD)
49.5 —
32.5 —
27.5 —
12.5 —
Fig. 10. Western ligand blot of plasma membrane-associated IGF binding
proteins. Membranes were prepared from saline perfused control and
ATN kidneys two days after the ischemic insult. Membranes were pooled
from 5 rats from each group and assayed in duplicate.
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Fig. 11. Relative IGF-I, IGF-I receptor and GH
receptor mRNA levels in kidneys from 5 ATN
(Li) rats and 5 pair-fed sham operated control
(VA) rats two days after swyely. Results were
analyzed as described in Fig. 6. Representative
autoradiograms are shown. < 0.05.
FIg. 12. Relative mRNA levels of IGFBP-1, -2,
-3, -4, and -5 in kidneys from 5 pair-fed control
and 5 A TN rats two days after injwy. mRNA
levels were detected by Northern blot analysis
and corrected for the 18S RNA levels. Results
were analyzed and expressed as described in
Fig. 6. Representative Northern blots from con-
trol (VA) and ATN (El) rats respectively are
shown. < 0.01.
the IGFBPs is unclear, but they do bind IGF-I with very high not stored in IGF-I producing cells. While the IGFBPs may
affinity and may serve as carrier delivering IGF-I to the target cells inhibit IGF-I action by reducing bioavailability, under selective
[16, 171. The IGFBPs may also serve as a circulating and tissue conditions some of the IGFBPs may actually enhance IGF-I
reservoir for IGF-I. This is potentially important since IGF-I is action [17]. Little is known about the action of the IGFBPs in the
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kidney. However, in preliminary studies with cultured rabbit
proximal tubular cells we have found that the IGFBPs produced
by these cells and as well as recombinant human IGFBP-3 inhibit
IGF-I action [42]. Taking together what little is known about the
actions of IGFBPs we offer for consideration the possibility that
the overall effect of reduced IGFBP mRNA and protein levels in
ischemic ATN may result in an increase in the bioavailability of
IGF-I.
While this study offers fresh insight into the response of the
renal GH—IGF-I axis to acute ischemic injury, it should be
recognized that the study was conducted at the whole kidney level
and thus reflects net changes in the kidney so that local changes
may be masked. Nevertheless, when interpreting these results
important general conclusions can be made which will serve as the
basis for further mechanistic studies into the local response to
acute tubular cell injury. Of particular interest are the observa-
tions that whole kidney mRNA levels for IGF-I and also several
IGFBPs are reduced, that kidney plasma membrane associated
IGFBPs are reduced and that kidney IGF-I receptor density is
increased. Taken together we propose that the low kidney IGF-I
mRNA levels in combination with the reduced kidney IGF-I
protein levels indicate an overall decrease in kidney IGF-I pro-
duction. This IGF-I deficiency will not favor tissue repair. On the
other hand, we offer for consideration the suggestion that reduced
kidney IGFBP gene expression with reduced IGFBP protein
levels together with an increase in IGF-I receptor number might
serve to offset the lowered kidney IGF-I production and also
enhance the reparative actions of circulating endogenous or
exogenous administered hormone.
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